Femasys Posts 40.8% Sales Gain, Starts FemBloc Trial and Secures $12M
Femasys reported 2025 sales of $2.29 million, up 40.8% year-over-year, and a net loss of $18.63 million while cash of $9.3 million supports operations into Q3 2026. The company initiated patient enrollment in its FDA-authorized FINALE pivotal trial for FemBloc, secured $12 million financing and achieved key regulatory clearances and partnerships.
1. Financial Performance
Femasys reported 2025 revenues of $2.29 million, a 40.8% increase from $1.63 million in 2024, driven by FemBloc sales. Research and development expenses declined 7.8% to $7.58 million, and net loss narrowed slightly to $18.63 million, or $0.47 per share.
2. Clinical and Regulatory Milestones
Patient enrollment commenced in the FDA-authorized FINALE pivotal trial evaluating FemBloc for non-surgical permanent birth control. FemBloc achieved Medical Device Single Audit Program certification, and the FemVue Controlled device received FDA 510(k) clearance, underpinning commercialization efforts.
3. Partnerships and Commercial Progress
The company secured a new Category III CPT code for FemaSeed intratubal insemination, paving the way for reimbursement. Strategic distribution was established with OR Consulting in Switzerland, and a collaboration with Refuah Health Center targets adoption of FemaSeed as first-line infertility treatment in community care.
4. Financing and Cash Position
Femasys completed a $12 million financing round, strengthening its balance sheet. Cash and equivalents totaled $9.3 million as of December 31, 2025, providing funding for operations into the third quarter of 2026.